Subscribe to Entrepreneur for $5
Subscribe

Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?

Sector ETF report for PJP

By
This story originally appeared on Zacks

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Dynamic Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on 06/23/2005.

- Zacks

While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among institutional and retail investors due to their low costs, transparency, flexibility, and tax efficiency.

Additionally, sector ETFs offer convenient ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Pharma is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 10, placing it in bottom 38%.

Index Details

The fund is sponsored by Invesco. It has amassed assets over $435.01 million, making it one of the average sized ETFs attempting to match the performance of the Healthcare - Pharma segment of the equity market. PJP seeks to match the performance of the Dynamic Pharmaceutical Intellidex Index before fees and expenses.

The Dynamic Pharmaceutical Intellidex Index is comprised of stocks of U.S. pharmaceutical companies. It is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.

Costs

When considering an ETF's total return, expense ratios are an important factor, and cheaper funds can significantly outperform their more expensive counterparts in the long term if all other factors remain equal.

Annual operating expenses for this ETF are 0.58%, making it on par with most peer products in the space.

It has a 12-month trailing dividend yield of 0.82%.

Sector Exposure and Top Holdings

It is important to delve into an ETF's holdings before investing despite the many upsides to these kinds of funds like diversified exposure, which minimizes single stock risk. And, most ETFs are very transparent products that disclose their holdings on a daily basis.

This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio.

Looking at individual holdings, Merck & Co Inc (MRK) accounts for about 6.99% of total assets, followed by Abbott Laboratories (ABT) and Eli Lilly & Co (LLY).

The top 10 holdings account for about 57.16% of total assets under management.

Performance and Risk

Year-to-date, the Invesco Dynamic Pharmaceuticals ETF has lost about -0.83% so far, and was up about 12.97% over the last 12 months (as of 01/05/2022). PJP has traded between $73.23 and $83.17 in this past 52-week period.

The ETF has a beta of 0.82 and standard deviation of 21.25% for the trailing three-year period, making it a high risk choice in the space. With about 23 holdings, it has more concentrated exposure than peers.

Alternatives

Invesco Dynamic Pharmaceuticals ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, PJP is a sufficient option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.

VanEck Pharmaceutical ETF (PPH) tracks MVIS US Listed Pharmaceutical 25 Index and the iShares U.S. Pharmaceuticals ETF (IHE) tracks Dow Jones U.S. Select Pharmaceuticals Index. VanEck Pharmaceutical ETF has $368.76 million in assets, iShares U.S. Pharmaceuticals ETF has $400.55 million. PPH has an expense ratio of 0.35% and IHE charges 0.42%.

Bottom Line

To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.



Infrastructure Stock Boom to Sweep America

A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.

The only question is “Will you get into the right stocks early when their growth potential is greatest?”

Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.

Download FREE: How to Profit from Trillions on Spending for Infrastructure >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports

 

Abbott Laboratories (ABT): Free Stock Analysis Report

 

Merck & Co., Inc. (MRK): Free Stock Analysis Report

 

Eli Lilly and Company (LLY): Free Stock Analysis Report

 

iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports

 

VanEck Pharmaceutical ETF (PPH): ETF Research Reports

 

To read this article on Zacks.com click here.